Clinical Trials

60 enrolled

Phase NA Not yet recruiting

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT07348965 2026-01-16

Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis

42 enrolled

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT07314216 2026-01-06

Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma

15 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07304739 2025-12-26

Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT06652048 2025-11-21

High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07193160 2025-09-25

Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy

45 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07087223 2025-07-25

Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure

Phase 1/2 Recruiting

42 enrolled

Non Small Cell Lung Cancer NSCLC

NCT04671303 2025-05-11

To Evaluate the Efficacy and Safety of Anlotinib Combined With Furmonertinib Mesylate in Lung Cancer

Phase 2 Completed

36 enrolled

Lung Neoplasms

NCT06674343 2024-11-05

Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations

Phase 3 Recruiting

144 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04322890 2024-10-22

PIKACHU

6,000 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06537297 2024-09-20

Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases

Carcinoma, Non-Small-Cell Lung

NCT05379803 2024-09-19

High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases

Carcinoma, Non-Small-Cell Lung

NCT06585644 2024-09-05

A Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC

44 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06394674 2024-07-26

High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib

84 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06483672 2024-07-03

LungBrain001

27 enrolled

Adenocarcinoma of Lung, Brain Neoplasms

NCT06452433 2024-06-11

Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.

91 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06352502 2024-04-08

An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis

Recruiting

EGF-R Positive Non-Small Cell Lung Cancer

NCT06339242 2024-04-01

A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal Metastasis

NSCLC

NCT06319950 2024-03-20

High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases

255 enrolled

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT06192849 2024-01-05

To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

20 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04401059 2023-12-27

SELECT-2

Phase 4 Recruiting

744 enrolled

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT06117644 2023-11-07

The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC

Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT05987826 2023-08-14

Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC

Carcinoma, Non-Small-Cell Lung

NCT05445310 2023-02-16

Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer

114 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04895930 2023-01-06

FOCUS-A

Carcinoma, Non-Small-Cell Lung

NCT05548348 2022-09-21

First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation

Carcinoma, Non-Small-Cell Lung

NCT05334277 2022-08-31

FOCUS-C

280 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05503667 2022-08-17

Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma

96 enrolled

Adenocarcinoma of Lung

NCT05255406 2022-08-04

Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE)

62 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05209256 2022-01-26

Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC

Phase 2/3 Unknown

90 enrolled

NSCLC

NCT05165355 2022-01-18

ATHEM

90 enrolled

NSCLC

NCT05079022 2021-10-15

ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas

Phase 1/2 Unknown

50 enrolled

Adenocarcinoma of Lung, Neoplasm, Residual

NCT04982900 2021-10-05

TERMGGO

138 enrolled

Multiple Primary Lung Cancers

NCT04970693 2021-07-21

A Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With Oligoprogression

64 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04965831 2021-07-16

Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT)